Trial Profile

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2025 According to an Amgen media release, results from this trial will be presented at upcoming congresses or published in peer-reviewed journals.
08 Mar 2025 Primary endpoint has been met. (Achievement of 75% reduction from baseline in Eczema Area and Severity Index (EASI) score at Week 24), according to an Amgen media release.
08 Mar 2025 Primary endpoint has been met. (Achievement of a Validated Investigators Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0 or 1 with 2 point reduction from baseline at Week 24), according to an Amgen media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com